Protection of Hair Cells from Ototoxic Drug-Induced Hearing Loss

Guo, Jinjun; Chai, Renjie; Li, Huawei; Sun, Shan

doi:10.1007/978-981-13-6123-4_2

Cited by 40 publications

(37 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was because aminoglycosides are preferentially localized at the base of cochlea, and both the aminoglycoside concentration and the extent of HC damage form a decreasing gradient from the base to the apex (Karasawa et al, 2008;Marcotti et al, 2010). Moreover, aminoglycoside-induced hearing loss also shows a decreasing gradient from high frequency to low frequency, which is consistent with the HC damage occurring primarily in the base and decreasing towards the apex (Chen et al, 2015;Guo et al, 2019). Because basal HCs are more sensitive to neomycin, we have paid the most attention to the protection of HCs in the basal turn.…”

Section: Discussionmentioning

confidence: 59%

“…Many studies, including our previous studies, have shown that caspase-associated apoptosis plays an important role in aminoglycoside-induced ototoxicity (Guan et al, 2016;He et al, 2017). The accumulation of ROS in the lysosomes and mitochondria of HCs leads to the upregulation of caspase genes, which further induces apoptosis of HCs (Esterberg et al, 2016;Jiang et al, 2016;Guo et al, 2019). In the central nervous system, myosin contraction plays an important role in oxidative stress-related neuronal apoptosis, myosin contraction, and the formation of relevant complexes needed to activate the expression of caspase-3 through the ROCK1-related pathway, indicating positive feedback regulation between myosin contraction and the oxidative stressinduced apoptosis pathway (Wang et al, 2017).…”

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Blebbistatin Inhibits Neomycin-Induced Apoptosis in Hair Cell-Like HEI-OC-1 Cells and in Cochlear Hair Cells

Gao

Cheng

Wang

et al. 2020

Front. Cell. Neurosci.

Self Cite

View full text Add to dashboard Cite

Aging, noise, and ototoxic drug-induced hair cell (HC) loss are the major causes of sensorineural hearing loss. Aminoglycoside antibiotics are commonly used in the clinic, but these often have ototoxic side effects due to the accumulation of oxygen-free radicals and the subsequent induction of HC apoptosis. Blebbistatin is a myosin II inhibitor that regulates microtubule assembly and myosin-actin interactions, and most research has focused on its ability to modulate cardiac or urinary bladder contractility. By regulating the cytoskeletal structure and reducing the accumulation of reactive oxygen species (ROS), blebbistatin can prevent apoptosis in many different types of cells. However, there are no reports on the effect of blebbistatin in HC apoptosis. In this study, we found that the presence of blebbistatin significantly inhibited neomycin-induced apoptosis in HC-like HEI-OC-1 cells. We also found that blebbistatin treatment significantly increased the mitochondrial membrane potential (MMP), decreased ROS accumulation, and inhibited pro-apoptotic gene expression in both HC-like HEI-OC-1 cells and explant-cultured cochlear HCs after neomycin exposure. Meanwhile, blebbistatin can protect the synaptic connections between HCs and cochlear spiral ganglion neurons. This study showed that blebbistatin could maintain mitochondrial function and reduce the ROS level and thus could maintain the viability of HCs after neomycin exposure and the neural function in the inner ear, suggesting that blebbistatin has potential clinic application in protecting against ototoxic drug-induced HC loss.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Introductionmentioning

confidence: 94%

Blebbistatin Inhibits Neomycin-Induced Apoptosis in Hair Cell-Like HEI-OC-1 Cells and in Cochlear Hair Cells

Gao

Cheng

Wang

et al. 2020

Front. Cell. Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Drug‐induced hearing loss is increasingly attracting attention . Our case suggests that oncologists should be aware of hearing loss as a rare potential side effect of regorafenib.…”

Section: What Is New and Conclusionmentioning

confidence: 89%

Bilateral sensorineural hearing loss induced by regorafenib

Cheng

Wang

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective: Regorafenib is a novel multi-targeted tyrosine kinase inhibitor approved for use in refractory metastatic colorectal cancer, advanced gastrointestinal stromal tumours and hepatocellular carcinoma. We report a case of bilateral sensorineural hearing loss caused by regorafenib. Case summary:A 48-year-old woman was diagnosed with colon cancer that had metastasized to the liver, ureter and left ovary. She was initially treated with oral regorafenib at the lowest recommended dosage of 80 mg/d for 2 weeks, at which point the dose was increased to 120 mg/d. On the second day after the regorafenib dosage increase (ie, 15 days after starting regorafenib), she suddenly developed a bilateral hearing loss. Regorafenib was discontinued immediately, and the patient was treated with a course of intravenous steroids. Five weeks later, her bilateral hearing had subjective partial improvement. What is new and conclusion:This is the first report of bilateral sensorineural hearing loss induced by regorafenib. K E Y W O R D S hearing loss, regorafenib, side effect How to cite this article: Cheng J, Wang L, Zhu L-N, Wang L. Bilateral sensorineural hearing loss induced by regorafenib. J Clin Pharm Ther. 2019;44:963-965. https ://doi.

show abstract

“…46 In addition, macrolides, chloramphenicols, vancomycin, polymyxins, and acetyl salicylic acid have been reported to cause HL. 37 Other Adequate oxygenation is necessary for the cochlea to maintain normal function; hypoxia and HL are closely related. Asphyxia can cause not only hypoxic-ischemic encephalopathy (HIE) but also ANSD.…”

Section: Ototoxic Drugsmentioning

confidence: 99%

Change to Hearing Loss–Related Risks and Screening in Preterm Infants

2020

View full text Add to dashboard Cite

Hearing loss is one of the most common congenital defects in infancy; it increases speech and language delays and adversely affects academic achievement and socialemotional development. The risk of hearing loss in premature infants is higher than that in normal newborns, and because of the fragility of the auditory nervous system, it is more vulnerable to different risk factors. The hearing screening guidelines in current use were proposed by the American Academy of Pediatrics and updated in 2007, but there are no uniform guidelines for hearing screening in preterm infants. This review focuses on the risk factors related to hearing loss in premature infants, hearing screening strategies, and reasons for failure. The aim is to provide a more comprehensive understanding of hearing development in preterm infants to achieve early detection and early intervention. At the same time, attention should be paid to delayed auditory maturation in preterm infants to avoid excessive intervention. Key Points

show abstract

Protection of Hair Cells from Ototoxic Drug-Induced Hearing Loss

Cited by 40 publications

References 105 publications

Blebbistatin Inhibits Neomycin-Induced Apoptosis in Hair Cell-Like HEI-OC-1 Cells and in Cochlear Hair Cells

Blebbistatin Inhibits Neomycin-Induced Apoptosis in Hair Cell-Like HEI-OC-1 Cells and in Cochlear Hair Cells

Bilateral sensorineural hearing loss induced by regorafenib

Change to Hearing Loss–Related Risks and Screening in Preterm Infants

Contact Info

Product

Resources

About